Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Bio­phar­ma R&D spend­ing re­bound­ed in 2023, up $11 bil­lion from 2022 fol­low­ing a steep post-pan­dem­ic de­cline. But the num­ber of new clin­i­cal tri­al starts slowed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER